Volcano Steps Up in Vulnerable Plaque By Buying Jomed's IVUS Business

For Volcano Therapeutics, the addition of Jomed's IVUS business is both an addition to and diversification beyond its current play in thermography as a diagnostic tool to detect vulnerable plaque.

For VolcanoTherapeutics Inc., the addition of Jomed NV 's IVUS business is both an addition to and diversification beyond its current play in thermography as a diagnostic tool to detect vulnerable plaque [See Deal].

As we noted in our profile of Volcano (see "Vulnerable Plaque Heats Up," IN VIVO, October 2002 Also see "

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.